UBA7 and neoplasm: It was the first Ubl shown to covalently modify proteins; its enzymatic cascade response is mediated by E1 (UBA7/UBE1L), E2 (UBCH8), and E3 ligases (HERC5 and HERC6) [26], and it is an antagonist of the ubiquitin pathway, which is abnormally elevated in various human malignancies, showing its potential role in tumor therapies.